Long-term follow-up after purine analogue therapy in hairy cell leukaemia

Best Practice and Research: Clinical Haematology

Volumn 28, Issue 4, 2015, Pages 217-229

  Else, Monica ^a   Dearden, Claire E ^b   Catovsky, Daniel ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Chemoimmunotherapy; Cladribine; Hairy cell leukaemia; Pentostatin; Purine analogue; Rituximab; Survival

Indexed keywords

CLADRIBINE; PENTOSTATIN; RITUXIMAB; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE; VEMURAFENIB;

ACUTE HEART INFARCTION; ACUTE MYELOBLASTIC LEUKEMIA; ANEMIA; ARTICLE; ASPERGILLOSIS; CANCER MORTALITY; CANCER PROGNOSIS; CAUSE OF DEATH; CHRONIC PATIENT; DRUG EFFICACY; FOLLOW UP; FRANCE; HAIRY CELL LEUKEMIA; HUMAN; LEUKEMIA RELAPSE; LEUKOCYTOSIS; LONG TERM SURVIVAL; LYMPHADENOPATHY; LYMPHOMA; MINIMAL RESIDUAL DISEASE; MYELOPROLIFERATIVE DISORDER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; SECOND CANCER; SEPSIS; SPAIN; SPLENOMEGALY; THROMBOCYTOPENIA; UNITED KINGDOM; ANTAGONISTS AND INHIBITORS; B LYMPHOCYTE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; LEUKEMIA, HAIRY CELL; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE; REMISSION; SURVIVAL ANALYSIS;

ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CLADRIBINE; FOLLOW-UP STUDIES; HUMANS; INDOLES; LEUKEMIA, HAIRY CELL; MUTATION; PENTOSTATIN; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RECURRENCE; REMISSION INDUCTION; RITUXIMAB; SULFONAMIDES; SURVIVAL ANALYSIS;

EID: 84983127970     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2015.09.004     Document Type: Review

References (49)

1. B.A. Bouroncle, B.K. Wiseman, and C.A. Doan Leukemic reticuloendotheliosis Blood 13 1958 609 630
2. A.S. Spiers, S.J. Parekh, and M.B. Bishop Hairy-cell leukemia: induction of complete remission with pentostatin (2'-deoxycoformycin) J Clin Oncol 2 1984 1336 1342
3. A.D. Ho, J. Thaler, F. Mandelli, F. Lauria, R. Zittoun, R. Willemze, and et al. Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. The European organization for research and Treatment of Cancer Leukemia Cooperative Group J Clin Oncol 7 1989 1533 1538
4. P.A. Cassileth, B. Cheuvart, A.S. Spiers, D.P. Harrington, F.J. Cummings, R.S. Neiman, and et al. Pentostatin induces durable remissions in hairy cell leukemia J Clin Oncol 9 1991 243 246
5. D. Catovsky, E. Matutes, J.G. Talavera, N.T. O'Connor, S.A. Johnson, E. Emmett, and et al. Long term results with 2'deoxycoformycin in hairy cell leukemia Leuk Lymphoma 14 Suppl. 1 1994 109 113
6. H.M. Golomb, R. Dodge, R. Mick, D. Budman, R. Hutchison, S.J. Horning, and et al. Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon: a report of CALGB study 8515 Leukemia 8 1994 2037 2040
7. E.H. Kraut, M.R. Grever, and B.A. Bouroncle Long-term follow-up of patients with hairy cell leukemia after treatment with 2-deoxycoformycin Blood 84 1994 4061 4063
8. M. Grever, K. Kopecky, M.K. Foucar, D. Head, J.M. Bennett, R.E. Hutchison, and et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study J Clin Oncol 13 1995 974 982
9. L.D. Piro, C.J. Carrera, D.A. Carson, and E. Beutler Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine N Engl J Med 322 1990 1117 1121
10. E.H. Estey, R. Kurzrock, H.M. Kantarjian, S.M. O'Brien, K.B. McCredie, M. Beran, and et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA) Blood 79 1992 882 887
11. G. Juliusson, and J. Liliemark Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2-deoxyadenosine (CdA): relation to opportunistic infections Blood 79 1992 888 894
12. M.A. Hoffman, D. Janson, E. Rose, and K.R. Rai Treatment of hairy cell leukemia with cladribine: response, toxicity, and long term follow-up J Clin Oncol 15 1997 1138 1142
13. B.D. Cheson, J.M. Sorensen, D.A. Vena, M.J. Montello, J.A. Barrett, E. Damasio, and et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients J Clin Oncol 16 1998 3007 3015
14. A. Saven, C. Burian, J.A. Koziol, and L.D. Piro Long-term follow-up of patients with hairy cell leukemia after cladribine treatment Blood 92 1998 1918 1926
15. C.E. Dearden, M. Else, and D. Catovsky Long-term results for pentostatin and cladribine treatment of hairy cell leukemia Leuk Lymphoma 52 Suppl. 2 2011 21 24
16. D. Sigal, R. Sharpe, C. Burian, and A. Saven Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine Blood 115 2010 1893 1896
17. C. Dearden, and M. Else Hairy cell leukemia. [review] Curr Oncol Rep 8 2006 337 342
18. P.L. Zinzani, C. Pellegrini, V. Stefoni, E. Derenzini, L. Gandolfi, A. Broccoli, and et al. Hairy cell leukemia: evaluation of the long-term outcome in 121 patients Cancer 116 2010 4788 4792
19. M. Else, C.E. Dearden, E. Matutes, J. Garcia-Talavera, A.Z. Rohatiner, S.A. Johnson, and et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis Br J Haematol 145 2009 733 740
20. M. Else, C.E. Dearden, E. Matutes, F. Forconi, F. Lauria, H. Ahmad, and et al. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence Leuk Lymphoma 52 Suppl. 2 2011 75 78
21. F. Ravandi, S. O'Brien, J. Jorgensen, S. Pierce, S. Faderl, A. Ferrajoli, and et al. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia Blood 118 2011 3818 3823
22. M. Leclerc, F. Suarez, M.P. Noël, A. Vekhoff, X. Troussard, J.F. Claisse, and et al. Rituximab therapy for hairy cell leukemia: a retrospective study of 41 cases Ann Hematol 94 2015 89 95
23. G. Juliusson, H. Samuelsson Swedish Lymphoma Registry Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy Leuk Lymphoma 52 Suppl. 2 2011 46 49
24. F. Lauria, E. Cencini, and F. Forconi Alternative methods of cladribine administration Leuk Lymphoma 52 Suppl. 2 2011 34 37
25. G. Jones, N. Parry-Jones, B. Wilkins, M. Else, D. Catovsky, and et al. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant. Compiled on Behalf of the clinical Task Force of the British Committee for standards in Haematology Br J Haematol 156 2012 186 195
26. E. Cornet, A. Delmer, P. Feugier, F. Garnache-Ottou, D. Ghez, V. Leblond, et al. French Society of Haematology Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia Ann Hematol 93 2014 1977 1983
27. T. Robak, E. Matutes, D. Catovsky, P.L. Zinzani, C. Buske, et al. on behalf of the ESMO Guidelines Working Group Hairy cell leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 26 Suppl. 5 2015 v100 v107
28. I.W. Flinn, K.J. Kopecky, M.K. Foucar, D. Head, J.M. Bennett, R. Hutchison, and et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin Blood 96 2000 2981 2986
29. J.B. Johnston, E. Eisenhauer, N. Wainman, W.E. Corbett, S.D. Zaentz, P.J. Daeninck, and et al. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study Semin Oncol 27 2 Suppl. 5 2000 32 36
30. M. Rafel, F. Cervantes, J.M. Beltrán, F. Zuazu, L. Hernández Nieto, C. Rayón, and et al. Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients Cancer 88 2000 352 357
31. G.R. Goodman, C. Burian, J.A. Koziol, and A. Saven Extended follow-up of patients with hairy cell leukemia after treatment with cladribine J Clin Oncol 21 2003 891 896
32. F. Maloisel, L. Benboubker, M. Gardembas, B. Coiffier, M. Divine, C. Sebban, and et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients Leukemia 17 2003 45 51
33. U. Jehn, R. Bartl, H. Dietzfelbinger, T. Haferlach, V. Heinemann, and et al. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine Leukemia 18 2004 1476 1481
34. P.L. Zinzani, M. Tani, E. Marchi, V. Stefoni, L. Alinari, G. Musuraca, and et al. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine Haematologica 89 2004 309 313
35. P. Chadha, A.W. Rademaker, P. Mendiratta, B. Kim, D.M. Evanchuk, D. Hakimian, and et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience Blood 106 2005 241 246
36. M. Else, R. Ruchlemer, N. Osuji, I. Del Giudice, E. Matutes, A. Woodman, and et al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years Cancer 104 2005 2442 2448
37. J.D. Rosenberg, C. Burian, J. Waalen, and A. Saven Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series Blood 123 2014 177 183
38. M. López Rubio, C. Da Silva, J. Loscertales, C. Seri, P. Baltasar, E. Colado, and et al. Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC) Leuk Lymphoma 55 2014 1007 1012
39. E. Cornet, C. Tomowiak, A. Tanguy-Schmidt, S. Lepretre, J. Dupuis, P. Feugier, et al. Société Française d'Hématologie Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia Br J Haematol 166 2014 390 400
40. S. Hacioglu, Y. Bilen, A. Eser, S. Sivgin, E. Gurkan, R. Yildirim, and et al. Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapy Hematol Oncol 2014 Nov 13 10.1002/hon. 2177 [Epub ahead of print]
41. V. Somasundaram, A. Purohit, M. Aggarwal, P. Manivannan, P. Mishra, T. Seth, and et al. Hairy cell leukemia: a decade long experience of North Indian Hematology Center Indian J Med Paediatr Oncol 35 2014 271 275
42. G.J. Ruiz-Delgado, L.C. Tarín-Arzaga, C. Alarcón-Urdaneta, J. Calderón-García, D. Gómez-Almaguer, G.J. Ruiz-Argüelles, and et al. Treatment of hairy cell leukemia: long-term results in a developing country Hematology 17 2012 140 143
43. F. Lauria, and F. Forconi Combination therapies to improve the long-term outcome in hairy cell leukemia Leuk Lymphoma 50 Suppl. 1 2009 18 22
44. L. Ginaldi, M. De Martinis, E. Matutes, N. Farahat, R. Morilla, D. Catovsky, and et al. Levels of expression of CD19 and CD20 in chronic B cell leukaemias J Clin Pathol 51 1998 364 369
45. A. Saven, and L.D. Piro Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2'-deoxycoformycin Ann Intern Med 119 1993 278 283
46. F. Forconi, E. Sozzi, E. Cencini, F. Zaja, T. Intermesoli, C. Stelitano, and et al. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior Blood 114 2009 4696 4702
47. E. Arons, T. Suntum, M. Stetler-Stevenson, and R.J. Kreitman VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy Blood 114 2009 4687 4695
48. F. Garnache Ottou, M.O. Chandesris, L. Lhermitte, C. Callens, K. Beldjord, M. Garrido, and et al. Peripheral blood 8 colour flow cytometry monitoring of hairy cell leukaemia allows detection of high-risk patients Br J Haematol 166 2014 50 59
49. M.R. Grever How I treat hairy cell leukemia Blood 115 2010 21 28